The Ledger

Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.

clear all ✕

why aren't all 4 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable

Opinion
Deming: Longevity is counterintuitively the least risky sector in biology
“I literally thought it was the least risky, most likely to work part of biology in general, particularly the part of biology that would be easy to test in humans, and that's very counterintuitive to most people.”
Laura Deming Nov 26, 2018 ▶ 12:52 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Disclosure
Deming: All Longevity Fund portfolio companies target multi-disease pathways
“All the companies that we invest in have drugs that have worked not just in kind of mouse models of Alzheimer's typically, but also diabetes and heart disease, and kind of typically the pathways that we invest in have been tested in and work in almost every Ag…”
Laura Deming Nov 26, 2018 ▶ 13:16 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Opinion
Deming: VC value creation is limited by rigid fund structure norms
“I think the diversity of fun types. I think we've been artificially constrained by a perception that it's hard to raise a new structure of fun because LPs just kind of, like, amorphously won't like it. I think that's really cut down on the value to be created …”
Laura Deming Nov 26, 2018 ▶ 26:15 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Disclosure
Laura Deming: The Longevity Fund pitched Unity Biotechnology to secure early LPs
“We had just found one of the first companies that we ever invested in, Unity Biotechnology, and we were really, really excited about them. And so I actually used that as the first Deal that I discussed with LPs.”
Laura Deming Nov 26, 2018 ▶ 19:47 20VC: Why Raising A First Time Fund Is Like Raising A Seed Round, Why We Need New and Different Fund Models & Why Longevity Is The Most Rewarding Place To Invest with Laura Deming, Founding Partner @ The Longevity Fund
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,200 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.